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Abstract
Objective: To assess the accuracy of pre-operative staging in patients with peripheral pancreatic
cystic neoplasms (pPCNs).
Methods: From 2005 to 2011, 148 patients underwent a pancreatectomy for pPCNs. The pre-operative
examination methods of computed tomography (CT), magnetic resonance imaging (MRI), endoscopic
ultrasonography (EUS) were compared for their ability to predict the suggested diagnosis accurately,
and the definitive diagnosis was affirmed by pathological examination.
Results: A mural nodule was detected in 34 patients (23%): only 1 patient (3%) had an invasive pPCN
at the final histological examination. A biopsy was performed in 79 patients (53%) during EUS: in 55
patients (70%), the biopsy could not conclude a diagnosis; the biopsy provided the correct and wrong
diagnosis in 19 patients (24%) and 5 patients (6%), respectively. A correct diagnosis was affirmed by
CT, EUS and pancreatic MRI in 60 (41%), 103 (74%) and 80 (86%) patients (when comparing EUS and
MRI; P = 0.03), respectively. The positive predictive values (PPVs) of CT, EUS and MRI were 70%,
75% and 87%, respectively.
Conclusions: Pancreatic MRI appears to be the most appropriate examination to diagnose pPCNs
accurately. EUS alone had a poor PPV. Mural nodules in a PCN should not be considered an indisput-
able sign of pPCN invasiveness.
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Introduction
Pancreatic cysts are uncommon, representing approximately
5% of all pancreatic neoplasms.1 The ability to differentiate
cystic neoplasms from pancreatic carcinoma and pseudocysts is
crucial to spare patients from high-morbidity surgery. In addi-
tion, there are histological subtypes of cystic neoplasms that
should be differentiated owing to their variable natural history.
On the one hand, a pancreatic cyst arising on the main pancre-
atic duct should be considered an intraductal papillary neo-
plasm (IPMN), and surgery is needed to spare the patient
from possible transformation of the cyst into invasive carci-
noma. On the other hand, the precise aetiology of ‘peripheral’
pancreatic cystic neoplasms (pPCNs; i.e. not arising on the
main pancreatic duct) is difficult to ascertain. Indeed, all other
subtypes except serous cystadenoma (SCA), which does not
have a malignant potential except rare reported cases, share
mucin-producing epithelia, and resection is recommended
because of the malignant potential. The mucinous subtypes
include mucinous cystadenoma (MCA), mucinous cystadeno-
carcinoma (MCADK), papillary cystic neoplasms and
IPMNs.1,2 Finally, some pPCNs might be resected, and the
final histology might affirm rare pancreatic cystic tumours (e.g.
neuroendocrine cystic tumours and pseudo papillary tumours).
In the late 1990s, subtypes of pPCNs have been deemed indis-
tinguishable without resection3 and have led to the recommen-
dation that all suspected pPCNs must be resected.4
Improvement in imaging techniques [e.g. magnetic resonance
imaging (MRI)] and endoscopic ultrasonography (EUS) associ-
ated with biopsies and/or fine needle aspiration (FNA) for cyst
fluid carcinoembryonic antigen (CEA) level measurement led
to an increase in the rate of appropriate pre-operative diagno-
ses. However, the accuracy of such examinations did not per-
mit 100% reliable diagnoses. A pancreatic surgeon facing a
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patient with a pPCN had to decide to resect it or not accord-
ing to pre-operative imaging. The present study was designed
so a pancreatic surgeon could be precise in which pre-opera-
tive imaging he could trust.
Patients and methods
From January 2005 to December 2011, 177 pancreatectomies
for pPCNs were performed at the Institut Paoli-Calmettes
(Marseille, France) and Ho^pital Nord (Marseille, France). All
of the patient data were entered prospectively into a clinical
database, which was approved by the institutional review board
of both institutions. A pPCN was defined by a unique or mul-
tiple cystic dilatation arising on pancreatic parenchyma with a
normal main pancreatic duct identified at pre-operative imag-
ing. Thus, all patients founded with the main pancreatic duct
over 3 mm were excluded from the study (i.e. main pancreatic
duct IPMNs or mixed IPMNs). Patients with a solid tumour
(adenocarcinoma of the pancreas, neuroendocrine tumour, car-
cinoma of the duodenum, distal common bile duct tumour or
ampulla of Vater tumour), IPMNs or invasive IPMNs arising
on the main pancreatic duct (including mixed IPMNs) were
excluded.
Pre-operative imaging
Pre-operative imaging included thin-section, contrast-
enhanced, helical dual-phase scanning (CT), and/or EUS with
or without pPCN biopsies, with or without FNA for CEA level
measurement according to the endoscopist’s preference/prac-
tice and/or pancreatic MRI. To reflect ‘real’ life, it was not
required that pre-operative imaging was performed obligatorily
at the institution that managed the patient. Indeed, some
examinations were performed closer to the patient’s home and
were not performed again to eliminate any bias owing to the
inexperience of the performing physician. For the present
study, patients were selected patients who underwent at least a
CT and EUS and/or pancreatic MRI. Thus, 148 patients com-
prised the present population study. After pre-operative imag-
ing, the aetiology of the pPCN suggested by each examination
was noted and compared with a final pathological examina-
tion.
Surgery
Surgery was performed using a laparotomy or a laparoscopic
approach according to the tumour site and surgeon/centre
preferences. Routine intra-operative section examination of the
pancreatic remnant was performed to ensure complete resec-
tion of supposed IPMNs; in case of enucleation, the communi-
cating duct was isolated and intra-operatively examined. A
total pancreatectomy was achieved in the case of pPCN spread;
enucleation was achieved if the pPCN was not close to the
main pancreatic duct (the complete procedure was already
described5).
Study parameters
The variables evaluated included: age, gender, maximal pPCN
size (mm), defined as the maximum diameter on pathological
analysis of the greater cyst in the case of multifocal disease,
uni- or multifocal repartition of the pPCN, the presence of a
mural nodule, cyst fluid CEA level measurement if performed
(UI/ml), pre-operative biopsy results if performed and a final
pathological examination.
Statistical analysis
Data analyses were performed using the GraphPad Prism soft-
ware, version 5.0d (GraphPad Software Inc., La Jolla, CA,
USA) and Microsoft Excel 2008 (Microsoft, Seattle, WA, USA).
Statistical associations among categorical factors were assessed
using Fisher’s exact test. Statistical significance was set at a
P-value less than 0.05.
Results
In this study, 94 patients (63.5%) underwent the 3 pre-opera-
tive examinations (i.e. CT, EUS and MRI), 93 patients under-
went pancreatic MRI (63%), 139 patients (94%) underwent EE
and a biopsy was performed in 79 patients (53%). The pPCN
was unifocal in 95 patients (64%); the median pPCN size was
28.4 mm (range, 7–230 mm). Information regarding patient
characteristics, pre-operative imaging and surgery are summa-
rized in Table 1.
Mural nodules
A mural nodule was detected in 34 patients (23%). All patients
with mural nodules underwent EUS and MRI. A mural nodule
was identified by both examinations in 12 patients (35%).
Mural nodules were only identified by EUS and MRI in 19
patients (56%) and 3 patients (9%), respectively. Only one
patient (3%) with a mural nodule identified at pre-operative
imaging had invasive IPMNs at the final pathological examina-
tion, 18 mural nodules (53%) showed mucin aggregation, 12
mural nodules were not retrieved (35%) and 3 mural nodules
(9%) were benign. No significant difference was noted between
EUS and MRI to identify the mural nodules correctly and pro-
vide the appropriate disease diagnosis.
Biopsies
In 55 patients (70%), the biopsy (n = 79) could not reveal the
diagnosis; according to final pathological examination, the
biopsy gave the correct and wrong diagnosis in 19 (24%) and
5 patients (6%), respectively.
Final pathological examination and correlation with
pre-operative examinations (Table 2)
The final pathological examination affirmed 77 non-invasive
branch duct IPMNs (52%), 38 MCAs (26%), 13 SCAs (9%),
8 neuroendocrine cystic tumours (5%), 7 pseudocysts (5%),
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3 invasive branch-duct IPMNs (2%), one pseudo papillary
tumour (0.5%) and one case of cystic dystrophy of the duo-
denal wall (0.5%). CT, EUS and MRI could not provide a
diagnosis in 54 patients (36.5%), 1 patient (0.7%) and 1
patient (1%), respectively. A correct diagnosis was affirmed
by CT, EUS and MRI in 60 patients (41%), 103 patients
(74%) and 80 patients (86%) (when comparing EUS and
MRI; P = 0.03), respectively. Biopsies and cyst fluid CEA level
measurement did not increase the EUS efficiency and MRI
remained the better technique to predict a pPCN diagnosis.
Hypothesizing that CT should have a better efficiency in
large pPCNs (arbitrarily set at 4 cm), the accuracy of CT
increased (54%) but remained significantly inferior to both
EUS and MRI. When considering patients with multifocal
cysts (n = 53), a correct diagnosis was affirmed by CT, EUS
and MRI in 35 patients (66%), 48 patients (91%) and 51
patients (96%) (when comparing EUS and MRI; P =NS),
respectively. In 14 patients, EUS and MRI did not suggest
the same diagnosis; in such a situation, the correct diagnosis
was affirmed by EUS and MRI in 4 patients (29%) and 8
patients (57%) (P =NS), respectively. The positive predictive
values (PPVs) of CT, EUS and MRI were 70%, 75% and
87%, respectively.
Discussion
Our study showed that (a) MRI seemed to be the best exami-
nation to predict the diagnosis of pPCNs, (b) mural nodules
were rarely (3%) associated with invasive pPCNs and (c)
biopsy and cyst fluid CEA level measurement showed a poor
efficiency and did not improve EUS accuracy.
Importantly, our study possessed several limitations. Indeed,
it was not explained why a pancreatectomy was performed (i.e.
pancreatitis, pain, or suspicion of invasive pPCNs). Thus, it
cannot be argued that patients who underwent a pancreatec-
tomy for SCA or a pseudocyst could have been spared from
surgery. Moreover, a proportion of the patients (14% in our
study) underwent a pancreatectomy for benign, non-degenera-
tive pPCNs owing to the imaging limitation to predict the
appropriate diagnosis. A second bias was the inability to differ-
entiate between patients who underwent pre-operative imaging
by an experienced physician. It is now accepted that the effi-
ciency of EUS and MRI is strongly related to the physician’s
experience, and it would be interesting to compare EUS and
MRI when performed by an experienced physician. However,
our purpose was to determine the best examination to predict
pPCN aetiology without consideration of the optimal situation
of all the examinations being performed by an experienced
Table 2 Correlation between final pathological examination and diagnosis suggested by a pre-operative CT scan, endoscopic





MRI diagnosis/FD (% RD)/p
when comparing with EUS
IPMNs 41/35 (85) 84/73 (87) 65/59 (91)/NS
MCA 36/21 (58) 36/21 (58) 17/13 (76)/NS
Invasive MCA 3/0 (0) 6/0 (0) 0/0 (0)/NS
SCA 7/3 (43) 6/4 (67) 6/5 (83)/NS
Other diagnosis 7/17 (41) 6/5 (83) 4/3 (75)/NS
Total 94/66 (45) 138/103 (74) 92/80 (86)/0.03
EUS, endoscopic ultrasonography; FD, final diagnosis; IPMNs, intra pancreatic mucinous neoplasms; MCA, mucinous cystic adenoma; MRI, mag-
netic resonance imaging; RD, right diagnosis; SCA, serous cystic adenoma.
Table 1 Characteristics and Preoperative Imaging of patients with
peripheral pancreatic cyst neoplasm
All patients (n = 148)
Gender ratio Male/Female 0.4
Mean age (range) 59.7 (32–78)
CT-scan (%) 148 (100)
No diagnosis suggested (%) 54 (36)
EUS (%) 139 (94)
With biopsy (%) 79 (53)
With FNA for CEA measurement (%) 57 (39)
No diagnosis suggested (%) 1 (0.7)
MRI (%) 93 (63)
No diagnosis suggested (%) 1 (1)
Unifocal Cyst (%) 95 (64)
Mean Cyst Size (mm) (SD) 28.4 (23.8)
Mural Nodule (%) 34 (23)
Mean cyst fluid CEA level (UI/Ml) (SD) 1133 (430.7)
Type of pancreatectomy
DP (%) 64 (43)
PD (%) 56 (38)
Enucleation (%) 14 (9)
MP (%) 10 (7)
TP (%) 4 (3)
CEA, carcinoembryonic antigen; DP, distal pancreatectomy; EUS,
endoscopic ultrasonography; FNA, fine needle aspiration; MP, median
pancreatectomy; MRI, magnetic resonance imaging; PD, pancreaticod
duodenectomy; TP, total pancreatectomy.
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physician. Indeed, a pancreatic surgeon who examines a patient
in the clinic who had already undergone EUS and/or MRI
would not repeat these examinations, particularly if the two
procedures produce concordant results. Finally, our study was
not a double-blind study: the physician, who performed EUS
or MRI, could know the diagnosis suggested by the previous
examination and was possibly influenced about his or her diag-
nosis.
All other subtypes, except serous SCA, that did not have a
malignant potential, share mucin-producing epithelia, and
their resection is recommended because of the malignant
potential. The major difficulty is to know the precise aetiol-
ogy of pPCNs to have an optimal therapeutic algorithm (i.e.
which patient must undergo resection and which patient
could be spared from surgery). CT is an efficient examina-
tion to detect pPCNs, but not to affirm their precise aetiol-
ogy. In our study, the PPV of CT was low [70% and always
inferior to EUS and MRI even under optimized situations
(large cysts or multifocal cyst)]. Thus, CT alone is a poor
examination option to predict pPCN aetiology and must be
completed by EUS or MRI. However, it was supposed that
the CT efficiency is under estimated: the physician who
performs CT for pPCNs did not make a fastidious study
because the patient is expected to undergo a supplementary,
more efficient examination.
At the end of the 20th century, resection of pPCNs has been
recommended because of the lack of efficiency of EUS and
MRI.4 However, both examinations improved owing to tech-
nology and physician improvement. Thus, recent guidelines6
recommend exploring pPCNs by CT and MRI. Indeed, the
complication rate with simultaneous FNA is low in highly
experienced centres,7 but EUS remains an invasive procedure.
Moreover, EUS morphology alone shows poor sensitivity and
specificity in accurately classifying pPCNs: cyst morphology on
EUS has an overall accuracy of 50–73%, and the sensitivity
and specificity for EUS amount to 56–71% and 45–97%,
respectively.8 When EUS is associated with cyst fluid CEA level
measurement, the results of cystic fluid analysis should always
be interpreted in conjunction with findings on CT/MRI and
EUS: EUS plus cyst fluid CEA level measurement can provide
diagnostic help in some uncertain cases.9 However, there is
currently no evidence to suggest EUS as a routine method for
the differential diagnosis of pPCNs. In our study, EUS had a
poor PPV (75%) and could not be associated with CT alone to
identify pPCN etiology precisely. Moreover, biopsy and CEA
level measurement did not sufficiently increase the EUS effi-
ciency to reach that of MRI. We supported that biopsies dur-
ing EUS are useless and did not have to be performed to
characterize pPCNs.
Regarding each pPCN aetiology in our study, it was noted
that MRI and EUS showed equal efficiency, but the overall effi-
ciency was significantly higher for MRI. MRI is not an invasive
procedure and is less dependent on physician experience. Thus,
in our experience, pancreatic MRI is the preferred examination
to characterize pPCNs, and it is supported that patients who
have undergone an MRI did not need an EUS. By contrast, it
is strongly recommended performing an MRI for a patient
with pPCNs who has already undergone CT and EUS. A recent
prospective study10 did not find an efficiency difference
between EUS and MRI, but the series comprised patients
whose examinations were all performed by an experienced
physician. We support that EUS and MRI may have the same
efficiency when performed by an experienced physician. How-
ever, the purpose of the present study was to determine which
examination a pancreatic surgeon might trust regardless of the
physician experience, a strategy that is a more realistic situa-
tion in everyday clinical practice.
Finally, it was surprisingly noted that the presence of a
mural nodule was not strongly associated with an invasive
pPCN (3%). Recently, Hirono et al.11 showed that a mural
nodule greater than 5 mm was a good predictor of invasive
IPMNs. The mural nodule size was not noted; thus, emphatic
conclusions about our findings could not be made. However,
we support that detection of a mural nodule is a frequent indi-
cation of a pancreatectomy but should not be considered an
indisputable sign of pPCN invasiveness.
Conclusions
In routine clinical practice (i.e. regardless of physician experi-
ence), pancreatic MRI seemed to be the most appropriate
examination and was performed in each patient with a pPCN
even if EUS had already been performed. EUS alone had a
poor PPV, and biopsy and/or cyst fluid CEA level measure-
ment did not permit EUS to reach the efficiency of MRI.
Mural nodules in a pPCN should not be considered an indis-
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